Biotech Buyouts Pile Up: What's Driving the M&A Frenzy?

Safety looked clean too. Only 9.5% of patients experienced treatment-related side effects, and none were serious. Two people discontinued due to nausea and skin burning (both mild).

Why Chiesi Wrote the $1.9 Billion Check

Chiesi offered $27 per share in cash, representing a 36% premium over KalVista's 30-day volume-weighted average price. The deal, structured as a tender offer followed by a merger, is expected to close in Q3 2026.

For Chiesi, this is the biggest acquisition in company history, surpassing the $1.25 billion it paid for Amryt Pharma in 2023. And it's not just about buying a drug; it's about buying a trajectory. Ekterly pulled in $49.1 million in global net product revenue during its first eight months on the market. That's a solid launch for a rare disease therapy.

Chiesi has set a revenue target of more than €6 billion by 2030, up from €3.6 billion in 2025. Ekterly is expected to be a meaningful contributor to that jump. More importantly, the acquisition gives Chiesi a stronger commercial footprint in the United States, where it has historically been a smaller player.

RBC Capital Markets noted that the deal "reflects strong strategic interest in the oral HAE space," validating the shift away from injectable therapies. No analyst coverage found a reason to pan the transaction. The consensus: fair price, smart strategy, clear upside.

The HAE Market Is Bigger Than You Think

Rare disease doesn't mean small market. The global HAE treatment market sits around $5.5 to $6.8 billion in 2026, depending on the estimate, and it's growing at 8-10% annually.

Here's what makes the landscape so attractive for acquirers: oral therapies are the fastest-growing segment, expanding at nearly 11-16% CAGR through 2031. Patients and doctors are voting with their prescriptions. Nobody wants to jab themselves with a needle during a sudden swelling attack if they can swallow a pill instead.

The market has been dominated by C1 esterase inhibitors (injected proteins that replace what HAE patients lack) and subcutaneous kallikrein inhibitors. Ekterly is a plasma kallikrein inhibitor too, but it works orally. That's the differentiator. Same mechanism, radically better delivery.

Five Deals, One Message

KalVista wasn't alone on the chopping block. The late-April/early-May blitz included:

• UCB acquiring Candid Therapeutics for up to $2.2 billion (autoimmune T-cell engager platform)
• Bayer acquiring Perfuse Therapeutics for up to $2.45 billion (ophthalmology)
• ARCHIMED taking Esperion Therapeutics private at a 58% premium (~$1.1 billion; cholesterol drugs)
• Pathos AI acquiring a majority stake in DeuterOncology (AI-driven oncology; terms undisclosed)

Each deal tells a slightly different story, but the common thread is unmistakable: big pharma and financial sponsors are buying commercial-stage or late-stage assets at full price. They're not kicking tires on preclinical science projects. They want revenue now, or revenue very soon.

This aligns with broader 2026 data showing that commercial-stage assets accounted for nearly half (49%) of total M&A value this year. Phase 3 assets make up another 28%. The message from boardrooms is clear: de-risked pipelines command premium prices.

Why Now? The Timing Isn't Coincidental

Several forces converged to create this M&A wave. First, many large pharma companies face patent cliffs in the next three to five years. Revenue gaps need filling, and internal R&D takes a decade to produce new blockbusters. Buying is faster.

Second, biotech valuations spent much of 2023 and 2024 in a trough. Companies like KalVista saw their stocks rise (KalVista was up 75% in the six months before the deal), but acquirers apparently still see room to pay premiums and generate returns.

Third, the regulatory environment for rare diseases remains favorable. Orphan drug designations, faster review pathways, and long exclusivity periods make these assets especially attractive. Once you own an approved rare disease therapy with few competitors, you've essentially built a toll road.

The Family Business Goes Big

One underappreciated angle: Chiesi is still a family-controlled company. Founded in 1935 by chemist Giacomo Chiesi in Parma, Italy, it's now in its third generation of family leadership. The company has more than 7,500 employees and sells medicines in over 100 countries.

For most of its history, Chiesi was known primarily for respiratory drugs (think inhalers for asthma) and neonatal therapies. Rare diseases became a strategic pillar more recently. The Amryt acquisition in 2023 was the first major signal. KalVista is the confirmation that rare disease isn't a side bet for Chiesi; it's the growth engine.

There's something compelling about a 91-year-old family pharma company making its largest-ever acquisition in a space (oral rare disease therapies) that barely existed a decade ago. It's a bet on the future from an institution built on patience.

What Happens Next

For KalVista shareholders, the path is straightforward: tender your shares at $27, collect cash, move on. The 36% premium is solid, though some might note the stock had already run up significantly. That said, certainty of value matters, and an all-cash deal with no financing contingencies removes execution risk.

For patients with HAE, the deal should accelerate global access. KalVista had approvals in the U.S., UK, EU, and Japan, with pediatric filings in progress. Chiesi's international infrastructure (31 affiliates, 100+ countries) gives Ekterly a runway that KalVista couldn't have built alone for years.

For the broader biotech ecosystem, this week was a signal flare. Companies with differentiated, approved therapies in rare diseases can expect to see suitors at the door. Oral delivery, in particular, seems to be catnip for acquirers. If your drug replaces an injection with a pill, your M&A premium just went up.

The deal tracker for 2026 now shows 31 completed or announced acquisitions. We're barely into May. At this pace, 2026 could set records. And if the past week taught us anything, it's that deals don't come one at a time anymore. They come in waves, each one raising the bar for the next.

Somewhere, a biotech CEO with a newly approved oral therapy is updating their investor deck. They should be. The buyers are hungry.

The Biotech IPO That Came Back From the Dead

Odyssey Therapeutics failed to IPO in 2025 when biotech markets froze. This week, the company raised $304 million in an upsized offering at the top of its price range. The resurrection says as much about investor appetite as it does about the company.